PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$4.89B
1-Year Est. Return
251.12%
This Fund
S&P 500
1 Year Est. Return
+251.12%
AUM
$4.89B
AUM Growth
+$1.16B
(+31%)
Holding
40
Top Buys
| 1 | +$193M | |
| 2 | +$187M | |
| 3 | +$121M | |
| 4 |
Cytokinetics
CYTK
|
+$94.1M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$91.4M |
Top Sells
| 1 | +$168M | |
| 2 | +$103M | |
| 3 | +$82.3M | |
| 4 |
ABVX
Abivax
ABVX
|
+$76.3M |
| 5 |
UroGen Pharma
URGN
|
+$55.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lexeo Therapeutics
LXEO
$354M
| $35.5M | 0.73% |
6,184,134
+1,420,936
|
|
||
|
MANE
27
Veradermics Inc
MANE
$4.1B
| $33.2M | 0.68% |
+525,000
|
|
||
28
Vor Biopharma
VOR
$740M
| $31.2M | 0.64% |
1,750,000
|
|
||
|
29
UroGen Pharma
URGN
$1.29B
| $30.6M | 0.63% |
1,703,949
-2,769,699
|
|
||
30
Structure Therapeutics
GPCR
$2.64B
| $26.3M | 0.54% |
+545,287
|
|
||
|
IVA
31
Inventiva
IVA
$855M
| $22.2M | 0.45% |
4,000,000
|
|
||
32
Oric Pharmaceuticals
ORIC
$789M
| $21.6M | 0.44% |
1,701,217
-700,000
|
|
||
33
Assembly Biosciences
ASMB
$485M
| $18.5M | 0.38% |
665,251
|
|
||
|
BBOT
34
BridgeBio Oncology
BBOT
$662M
| $7.77M | 0.16% |
868,213
-1,393,536
|
|
||
|
KLRS
35
Kalaris Therapeutics
KLRS
$111M
| $4.04M | 0.08% |
700,000
|
|
||
36
BridgeBio Pharma
BBIO
$12.5B
| – | – |
-684,277
|
|
||
|
CDTX
37
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-759,565
|
|
||
38
Crinetics Pharmaceuticals
CRNX
$3.44B
| – | – |
-2,210,774
|
|
||
39
Ocular Therapeutix
OCUL
$1.82B
| – | – |
-2,935,284
|
|
||
40
State Street SPDR S&P Biotech ETF
XBI
$7.78B
| – | – |
0
|
|